120 related articles for article (PubMed ID: 5003621)
21. The effect of dibromodulcitol (NSC 104800) on intravenously induced cytemia of rats.
Németh L
Neoplasma; 1971; 18(5):533-7. PubMed ID: 5119525
[No Abstract] [Full Text] [Related]
22. Chemotherapy research nurse.
Hubbard S; Devita V
Am J Nurs; 1976 Apr; 76(4):560-5. PubMed ID: 818899
[No Abstract] [Full Text] [Related]
23. Potential antitumor agents. Some 1,6-disubstituted galactitol and mannitol derivatives.
Acton EM; Keyanpour-Rad M; Christensen JE; Tong HH; Kwok RP; Goodman L
Carbohydr Res; 1972 May; 22(2):477-86. PubMed ID: 5047748
[No Abstract] [Full Text] [Related]
24. Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease.
DeConti RC; Mitchell MS; Marsh JC; Bertino JR
Cancer Chemother Rep; 1971 Dec; 55(5):607-10. PubMed ID: 4946083
[No Abstract] [Full Text] [Related]
25. Phase II trial of dianhydrogalactitol in the treatment of children with refractory childhood malignancies: a report from the Children's Cancer Study Group.
Finklestein JZ; Shore N; Krivit W; Hammond D; Higgins G
Cancer Treat Rep; 1985 Nov; 69(11):1331-3. PubMed ID: 4092198
[No Abstract] [Full Text] [Related]
26. Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313).
Németh L; Institóris L; Somfai S; Gál F; Pályi I; Sugár J; Csuka O; Szentirmay Z; Kellner B
Cancer Chemother Rep; 1972 Oct; 56(5):593-602. PubMed ID: 4652589
[No Abstract] [Full Text] [Related]
27. Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
Ahmann DL; O'Connell MJ; Bisel HF; Edmonson JH; Hahn RG; Frytak S
Cancer Treat Rep; 1977; 61(1):81-2. PubMed ID: 324622
[No Abstract] [Full Text] [Related]
28. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.
Institóris E; Szikla K; Otvös L; Gál F
Cancer Chemother Pharmacol; 1989; 24(5):311-3. PubMed ID: 2758560
[TBL] [Abstract][Full Text] [Related]
29. Preclinical toxicology of alpha-2'-deoxythioguanosine (NSC-71851).
Henry MC; DiDomenico E
Cancer Chemother Rep 3; 1974 Sep; 5(1):9-14. PubMed ID: 4213304
[No Abstract] [Full Text] [Related]
30. The absorption and metabolism of dibromodulcitol in patients with advanced cancer.
Belej MA; Troetel WM; Weiss AJ; Stambaugh JE; Manthei RW
Clin Pharmacol Ther; 1972; 13(4):563-72. PubMed ID: 5042371
[No Abstract] [Full Text] [Related]
31. Auto-immune haematological complications occurring during the treatment of malignant lymphoproliferative diseases.
Ludwin D; Sacks P; Lynch S; Jacobs P; Bezwoda W; Bothwell TH
S Afr Med J; 1974 Oct; 48(51):2143-5. PubMed ID: 4479692
[No Abstract] [Full Text] [Related]
32. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT
Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941
[TBL] [Abstract][Full Text] [Related]
33. Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.
Eagan RT; Ingle JN; Frytak S; Rubin J; Kvols LK; Carr DT; Coles DT; O'Fallon JR
Cancer Treat Rep; 1977 Oct; 61(7):1339-45. PubMed ID: 589599
[No Abstract] [Full Text] [Related]
34. Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313).
Eagan RT; Moertel CG; Hahn RG; Schutt AJ
J Natl Cancer Inst; 1976 Jan; 56(1):179-81. PubMed ID: 943554
[TBL] [Abstract][Full Text] [Related]
35. Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
Creagan ET; Eagan RT; Rubin J
Med Pediatr Oncol; 1979; 7(2):179-80. PubMed ID: 502975
[No Abstract] [Full Text] [Related]
36. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.
Young RC; DeVita VT; Serpick AA; Canellos GP
N Engl J Med; 1971 Aug; 285(9):475-9. PubMed ID: 5558887
[No Abstract] [Full Text] [Related]
37. Preliminary pharmacological studies with 1,6-dimesyl-2,3-4,5-dianhydro-L-iditol in patients with cancer.
Csetényi J; Bihari V; Számel SI; Horváth IP; Eckhardt S
Eur J Cancer (1965); 1975 Sep; 11(9):675-6. PubMed ID: 176030
[No Abstract] [Full Text] [Related]
38. Initial clinical trials with 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NCS-112682).
Luce JK; Bodey GP
Cancer Chemother Rep; 1970 Apr; 54(2):131-4. PubMed ID: 4946003
[No Abstract] [Full Text] [Related]
39. Clinical experience with a new anticancer agent, carbazilquinone (NSC-134679).
Saito T; Oira S; Wakui A; Yokoyama M; Takahashi H
Cancer Chemother Rep; 1973; 57(4):447-57. PubMed ID: 4586952
[No Abstract] [Full Text] [Related]
40. Phase II study of dibromodulcitol (NSC-104800).
Andrews NC; Weiss AJ; Wilson W; Nealon T
Cancer Chemother Rep; 1974; 58(5 Pt 1):653-60. PubMed ID: 4426045
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
